McDonald's shares have surged over 20% in a month, driven by improved U.S. traffic and value pricing strategies. However, debate persists among investors: one argues that GLP-1 weight-loss drugs could reduce demand for fast food long-term, while another highlights McDonald's valuable real estate holdings and strong operating margins. Key factors to watch include whether traffic gains continue, franchisees' adherence to value pricing, and any impact from weight-loss drugs on customer visits. The stock trades at a P/E of about 23, reflecting mixed investor views.
McDonald's commands a market cap of $198.30 billion and offers a dividend yield of 2.75%, highlighting its scale and income potential as of Nov 05, 2026 20:12 WIB. The stock trades at USD 281.90 on Pluang with a modest 1-day gain of 0.60%, while trading volume reached over 11.5 million shares. Despite a high sell order activity of 90%, investors hold shares for an average of 166 days, indicating a medium-term commitment to the stock.
McDonald's is showing signs of a successful turnaround as US same-store sales improved, declining only 0.2% in Q3 versus an expected 0.5%, and returned to growth in September. The company has refocused on value offerings and digital promotions, which...
McDonald's has started an eight-week trial of new value menu options in about 1,900 U.S. restaurants, introducing mix-and-match combos and fixed bundles. This move aims to strengthen its value proposition as visits to its outlets fell 6.2% in the thi...
McDonald's shares rose 5% after the company reported Q3 earnings that beat expectations with adjusted EPS of $3.57 versus $3.38 expected, despite a 0.2% decline in U.S. same-store sales. The revenue missed estimates slightly at $7.16 billion versus $...
McDonald's reported improving US sales driven by promotions like $2 breakfast sandwiches and free fries, helping recover customers amid cost-of-living pressures. Despite a 4.6% drop in customer visits in Q3 and a slight 0.2% decline in same-store sal...
CVS Health and McDonald's are set to report earnings soon, with both stocks labeled 'too cheap to ignore' by Jim Cramer despite underlying risks. CVS has shown strong earnings growth and raised its full-year guidance, but faces potential policy risks...
